Drugs / E7 TCR-T cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05639972 | Aug 2025 → Oct 2026 expected | adenosquamous carcinoma, anal squamous cell carcinoma, endocervical adenocarcinoma, human papillomavirus-related penile squamous cell carcinoma +3 | Christian Hinrichs | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05686226 | Mar 2023 → Jan 2027 expected | adenosquamous carcinoma, anal squamous cell carcinoma, endocervical adenocarcinoma, human papillomavirus-related penile squamous cell carcinoma +4 | Christian Hinrichs | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E7 TCR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05686226 ↗ |
| Action | Deplete | “The intent of E7 TCR-T cell treatment is to shrink or eliminate tumors and thereby facilitate definitive therapy and increase overall survival.” NCT05639972 ↗ |
| Modality | Cell therapy | “Participants will undergo an apheresis procedure to obtain T cells that will be genetically engineered to generate E7 TCR-T cells.” NCT05639972 ↗ |
| Route | Intravenous | “E7 TCR-T cells will be administered as a single intravenous infusion.” NCT05639972 ↗ |